Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of sunitinib rechallenge in metastatic renal cell carcinoma
2012-002891-15Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- Sep 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in clear cell renal cell carcinoma (ccRCC), sponsored by VU University Medical Center. Primary endpoint: Progression-free at 3 months. Started Sep 2012; status: terminated.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2012-002891-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002891-15.